BLFS earnings analysis
What we found in BLFS's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
BioLife Solutions demonstrated a robust start to 2026 with a revenue of $27.5 million, marking a 25% increase compared to the prior year. The company reported an earnings per share (EPS) of $0.04, surpassing estimates and contributing to a positive outlook despite slight declines in gross margin. Cash reserves decreased from $120.2 million at the end of 2025 to $111.5 million, influenced by investment activities and cash flow from operations.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Increased by 25%
- Total revenue reached $27.5 million for Q1 2026, up from $22.05 million in Q1 2025.
- EPS Beat Expectations
- Diluted EPS improved to $0.04, exceeding the expected $0.02 by 100%.
- Operating Margin Improvement
- Despite slight margin compression, the operating margin improved to 7.9% from negative margins in previous quarters.
- Cash Flow from Operations
- While cash used in operating activities was $(0.5) million, this reflects previous cash flow dynamics rather than operational weaknesses.
- Positive Interest Income Growth
- Interest income increased by 52%, reaching $1.04 million, benefiting from higher investment returns.
- Continued Investment in R&D
- R&D expenses increased by 84% to $2.65 million, indicating strong commitment to innovation.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Margin Compression
- Gross margin decreased to 64% from 67% year-over-year, driven by a shift to lower-margin products.
- Cash Reserves Decrease
- Cash and cash equivalents dropped to $111.5 million from $120.2 million, raising liquidity concerns.
- Operational Cash Flow Decline
- Net cash used in operating activities changed from a positive $1.7 million in Q1 2025 to a negative $0.5 million in Q1 2026.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.04
- Gross margin
- 64%
- Operating margin
- 7.9%
What they said about what is next.
Revenue guidance for 2026 remains reiterated at $112.5 million to $115 million, anticipating 17% to 20% growth compared to 2025.
The filing reads better than the one before it.
What came before.
- 10-K · April 28, 2026
- BioLife Solutions' 2025 10-K reflects a period of strategic realignment resulting in significant top-line growth despite ongoing operational challenges. With revenue increasing notably and consistent gross margins, the…
- 10-K · February 26, 2026
- BioLife’s 2025 10‑K shows a company reshaping its portfolio (multiple divestitures) while growing product revenue and investing in biopreservation R&D (PanTHERA acquisition). Full‑year revenue improved materially versus…
- 10-Q · August 7, 2025
- BioLife reported Q2 2025 total revenue of $25,421,000, up $5,706,000 (≈29%) versus Q2 2024, driven by product revenue growth. GAAP operating loss widened to $(16,643,000) (operating margin -65.5%) primarily due to a…
- 10-Q · May 8, 2025
- BioLife Solutions reported significant revenue growth in Q1 2025 with total revenue of $23.941 million, marking an increase of 30.0% from $18.433 million year-over-year. The gross margin remained strong at 65.9%,…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing BLFS makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever